[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657222":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":45,"studyPopulation":46,"armGroups":47,"interventions":41,"overallOfficials":41,"centralContacts":54,"locations":60,"responsibleParty":78,"collaborators":41,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":41,"enrollmentInfo":92,"targetDuration":41,"studyType":95,"phases":41,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":104,"whyStopped":41,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Zhongda Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":41},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival(OS)","The OS is defined as the time from the initiation of any combination treatment to death due to any cause.","up to approximately 2 years",[14,17,20,23,26,29,32,35,38],{"measure":15,"description":16,"timeFrame":12},"Progression free survival(PFS) per RECIST 1.1","The PFS is defined as the time from the initiation of any combination treatment to the first documented progressive disease (according to RECIST 1.1) or death due to any cause, whichever occurs first.",{"measure":18,"description":19,"timeFrame":12},"PFS per mRECIST","The PFS is defined as the time from the initiation of any combination treatment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first.",{"measure":21,"description":22,"timeFrame":12},"Objective response rate(ORR) per RESCIST 1.1","The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1.",{"measure":24,"description":25,"timeFrame":12},"Duration of Response (DOR) per RESCIST 1.1","DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR until the first documented disease progression (according to RESCIST 1.1) or death due to any cause, whichever occurs first.",{"measure":27,"description":28,"timeFrame":12},"Disease Control Rate (DCR) per RESCIST 1.1","DCR is defined as the percentage of participants who have a best overall response of CR, PR, or stable disease (SD)per RESCIST 1.1.",{"measure":30,"description":31,"timeFrame":12},"ORR per mRECIST","The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST.",{"measure":33,"description":34,"timeFrame":12},"DOR per mRECIST","DOR is determined by disease assessment and is defined as the time from the first documented evidence of a response of CR or PR until the first documented disease progression (according to mRECIST) or death due to any cause, whichever occurs first.",{"measure":36,"description":37,"timeFrame":12},"DCR per mRECIST","DCR is defined as the percentage of participants who have a best overall response of CR, PR, or stable disease (SD) per mRECIST.",{"measure":39,"description":40,"timeFrame":12},"Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0","The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0.",null,{"allocation":41,"interventionModel":41,"interventionModelDescription":41,"primaryPurpose":41,"observationalModel":43,"timePerspective":44,"maskingInfo":41},"COHORT","RETROSPECTIVE","Transarterial chemoembolization (TACE) can induce immunogenic cell death and tumor-specific immune response which results in the release of tumor antigens and transform \"cold\" tumors with lacking immune effector cells into \"hot\" tumors with immune effector cells infiltration. This provides a theoretical basis for TACE combined with immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) patients. Tislelizumab is a PD-1 monoclonal antibody approved by the National Medical Products Administration (NMPA) of China for first-line and second-line treatment of patients with HCC. The purpose of this real-world study is to evaluate the safety and efficacy of TACE in combination with Tislelizumab and Lenvatinib in patients with advanced-stage HCC.","Patients with advanced HCC who received Tislelizumab and Lenvatinib with\u002Fwithout TACE under real-world practice conditions.",[48,51],{"label":49,"type":41,"description":50,"interventionNames":41},"Study group","TACE + Tislelizumab + Lenvatinib TACE was performed within 3 months before or after the first Tislelizumab \u002FLenvatinib treatment. The interval between first use Tislelizumab and Lenvatinib ≤1 week；",{"label":52,"type":41,"description":53,"interventionNames":41},"Control group","Tislelizumab + Lenvatinib The interval between first use Tislelizumab and Lenvatinib ≤1 week；",[55],{"name":56,"role":57,"phone":58,"phoneExt":41,"email":59},"Zhicheng Jin, M.D., Ph.D.","CONTACT","+86-025-83272121","jinzhic@foxmqil.com",[61],{"facility":62,"status":41,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Zhongda Hospital, School of Medicine, Southeast University","Nanjing","Jiangsu","210009","China","CN",{"type":69,"coordinates":70},"Point",[71,72],118.77778,32.06167,{"lat":72,"lon":71},[75,77],{"name":76,"role":57,"phone":41,"phoneExt":41,"email":41},"Zhicheng Jin",{"name":41,"role":57,"phone":58,"phoneExt":41,"email":41},{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"PRINCIPAL_INVESTIGATOR","Gao-jun Teng","Dr. Prof. , President","100657222","tace-in-combination-with-tislelizumab-and-lenvatinib-for-advanced-hcc-chance2602-100657222",false,"NCT07836309","TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)","Efficacy and Safety of Transarterial Chemoembolization in Combination With Tislelizumab and Lenvatinib for Advanced Stage HCC (CHANCE2602)","CHANCE2602","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or patients who meet the clinical diagnostic criteria for primary liver cancer;\n2. Age ≥18 years at the time of HCC diagnosis;\n3. Barcelona Clinic Liver Cancer (BCLC) stage C;\n4. No prior systemic therapy for HCC (including chemotherapy, molecular targeted therapy, or immunotherapy);\n5. Received treatment with tislelizumab and lenvatinib, with the interval between the first administration of the two drugs ≤1 week;\n6. In the experimental group, TACE was performed within 3 months before or after treatment with tislelizumab and lenvatinib;\n7. After TACE, patients received at least one cycle of combination therapy with tislelizumab and lenvatinib, including cTACE and DEB-TACE;\n8. Child-Pugh class A5 to B7;\n9. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;\n10. At least one measurable intrahepatic lesion according to RECIST 1.1 criteria.\n\nExclusion Criteria:\n\n1. Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma histological types;\n2. Complete obstruction of the main portal vein with insufficient collateral compensation;\n3. Uncontrollable ascites or hepatic encephalopathy;\n4. Incomplete clinical data or missing essential information;\n5. Presence of other primary malignant tumors in addition to the diagnosis of liver cancer;\n6. Participation in other interventional studies prior to treatment;\n7. Other conditions deemed unsuitable for inclusion by the investigators.","ALL","16 Years",{"count":93,"type":94},596,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).",[98],"Hepatocellular Carcinoma (HCC)",[100,101,102,103],"TACE","Tislelizumab","Lenvatinib","HCC","NOT_YET_RECRUITING","2026-09-17",{"date":107,"type":108},"2026-09-23","ACTUAL",{"date":110,"type":94},"2026-09-30",{"date":112,"type":94},"2027-12-31",{"name":5,"class":6},1]